Trial Profile

A Prospective, Multicentre, Epidemiological Study Assessing the Impact of Childhood Vaccination with PCV13 and PCV7 on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) in Immunocompetent Adults Hospitalized with Community Acquired Pneumonia (CAP)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
Indications Community-acquired pneumonia
Focus Therapeutic Use
Acronyms CAPA
Sponsors Pfizer

14 Apr 2021 Results published in the Clinical Infectious Diseases
16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
24 Apr 2018 Results of a study investigating specific serotypes causing pneumococcal CAP presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com